1. Home
  2. NOAH vs BCYC Comparison

NOAH vs BCYC Comparison

Compare NOAH & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOAH
  • BCYC
  • Stock Information
  • Founded
  • NOAH 2005
  • BCYC 2009
  • Country
  • NOAH China
  • BCYC United Kingdom
  • Employees
  • NOAH N/A
  • BCYC N/A
  • Industry
  • NOAH Investment Managers
  • BCYC Biotechnology: Pharmaceutical Preparations
  • Sector
  • NOAH Finance
  • BCYC Health Care
  • Exchange
  • NOAH Nasdaq
  • BCYC Nasdaq
  • Market Cap
  • NOAH 618.3M
  • BCYC 566.5M
  • IPO Year
  • NOAH 2010
  • BCYC 2019
  • Fundamental
  • Price
  • NOAH $10.29
  • BCYC $8.22
  • Analyst Decision
  • NOAH Hold
  • BCYC Buy
  • Analyst Count
  • NOAH 3
  • BCYC 10
  • Target Price
  • NOAH $12.50
  • BCYC $25.00
  • AVG Volume (30 Days)
  • NOAH 81.2K
  • BCYC 333.0K
  • Earning Date
  • NOAH 05-28-2025
  • BCYC 05-01-2025
  • Dividend Yield
  • NOAH 20.61%
  • BCYC N/A
  • EPS Growth
  • NOAH N/A
  • BCYC N/A
  • EPS
  • NOAH 0.96
  • BCYC N/A
  • Revenue
  • NOAH $353,619,651.00
  • BCYC $25,722,000.00
  • Revenue This Year
  • NOAH N/A
  • BCYC N/A
  • Revenue Next Year
  • NOAH $6.37
  • BCYC $1.83
  • P/E Ratio
  • NOAH $10.69
  • BCYC N/A
  • Revenue Growth
  • NOAH N/A
  • BCYC N/A
  • 52 Week Low
  • NOAH $7.14
  • BCYC $6.10
  • 52 Week High
  • NOAH $14.90
  • BCYC $28.67
  • Technical
  • Relative Strength Index (RSI)
  • NOAH 60.74
  • BCYC 49.16
  • Support Level
  • NOAH $9.31
  • BCYC $8.00
  • Resistance Level
  • NOAH $10.91
  • BCYC $8.73
  • Average True Range (ATR)
  • NOAH 0.36
  • BCYC 0.48
  • MACD
  • NOAH 0.09
  • BCYC 0.02
  • Stochastic Oscillator
  • NOAH 61.25
  • BCYC 33.33

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: